scholarly journals Editorial: tissue findings fail to predict disease activity or prognosis in microscopic colitis—an opportunity to look at the molecular level—authors' reply

2021 ◽  
Vol 54 (2) ◽  
pp. 194-195
Author(s):  
Lærke Müller Olsen ◽  
Peter Johan Heiberg Engel ◽  
Danny Goudkade ◽  
Vincenzo Villanacci ◽  
Jeppe Thagaard ◽  
...  
Keyword(s):  
Disease Activity ◽  
Molecular Level ◽  
Microscopic Colitis

Development of a Microscopic Colitis Disease Activity Index: A Prospective Cohort Study

2016 ◽  
Vol 111 ◽  
pp. S64-S65
Author(s):  
Thomas Cotter ◽  
Moritz Binder ◽  
Patricia Kammer ◽  
Thomas Smyrk ◽  
William S. Harmsen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Disease Activity ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Activity Index ◽  
Disease Activity Index ◽  
Microscopic Colitis

Disease Activity Patterns, Mortality, and Colorectal Cancer Risk in Microscopic Colitis: A Danish Nationwide Cohort Study, 2001 to 2016

2020 ◽  
Author(s):  
Petra Weimers ◽  
Dorit Vedel Ankersen ◽  
Søren Lophaven ◽  
Ole Kristian Bonderup ◽  
Andreas Münch ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Disease Activity ◽  
Cox Regression ◽  
Severe Disease ◽  
Activity Patterns ◽  
Microscopic Colitis ◽  
Mortality Data ◽  
Disease Course ◽  
Background Population ◽  
Incident Cases

Abstract Background and Aims The disease course of microscopic colitis [MC], encompassing collagenous colitis [CC] and lymphocytic colitis [LC], is not well known. In a Danish nationwide cohort, we evaluated the disease activity patterns as well as the risk of colorectal cancer [CRC] and mortality based on disease severity. Methods All incident MC patients [n = 14 302] with a recorded diagnosis of CC [n = 8437] or LC [n = 5865] in the Danish Pathology Register, entered between 2001 and 2016, were matched to 10 reference individuals [n = 142 481]. Incident cases of CRC after the index date were captured from the Danish Cancer Registry. Mortality data were ascertained from the Danish Registry of Causes of Death, and information about treatment was obtained from the Danish National Prescription Registry. The risk of CRC and mortality analyses were investigated by Cox regression and Kaplan-Meier estimates. Results We identified a self-limiting or transient disease course in 70.6% of LC patients and in 59.9% of CC patients, p <0.001. Less than 5% of MC patients experienced a budesonide-refractory disease course and were treated with immunomodulators or biologic treatment. A total of 2926 [20.5%] MC patients and 24 632 [17.3%] reference individuals died during the study period. MC patients with a severe disease had a relative risk [RR] of mortality of 1.41 (95% confidence interval [CI]: 1.32–1.50) compared with reference individuals. Only 90 MC patients were diagnosed with CRC during follow-up, corresponding to an RR of 0.48 [95% CI: 0.39–0.60]. Conclusions A majority of MC patients experience an indolent disease course with a lower risk of developing CRC compared with the background population.

Histological disease activity in patients with microscopic colitis is not related to clinical disease activity or long‐term prognosis

2021 ◽  
Author(s):  
Lærke Müller Olsen ◽  
Peter Johan Heiberg Engel ◽  
Danny Goudkade ◽  
Vincenzo Villanacci ◽  
Jeppe Thagaard ◽  
...  
Keyword(s):  
Disease Activity ◽  
Microscopic Colitis ◽  
Clinical Disease ◽  
Clinical Disease Activity ◽  
Long Term Prognosis

The Association of Serologic Inflammatory Markers with Microscopic Colitis Disease Activity

2011 ◽  
Vol 106 ◽  
pp. S164-S165
Author(s):  
Rami Abboud ◽  
Darrell Pardi ◽  
William Tremaine ◽  
William Sandborn ◽  
Patricia Kammer ◽  
...  
Keyword(s):  
Disease Activity ◽  
Inflammatory Markers ◽  
Microscopic Colitis

Derivation of a Microscopic Colitis Disease Activity Index (MCDAI)

2011 ◽  
Vol 106 ◽  
pp. S492-S493
Author(s):  
Darrell Pardi ◽  
Rami Abboud ◽  
Meredith McNally ◽  
William Tremaine ◽  
William Sandborn ◽  
...  
Keyword(s):  
Disease Activity ◽  
Activity Index ◽  
Disease Activity Index ◽  
Microscopic Colitis

The process of developing a disease activity index in microscopic colitis

2021 ◽  
Author(s):  
Katarina Pihl Lesnovska ◽  
Andreas Münch ◽  
Henrik Hjortswang
Keyword(s):  
Disease Activity ◽  
Content Validity ◽  
Activity Index ◽  
Disease Activity Index ◽  
Patient Reported Outcome Measures ◽  
Postal Survey ◽  
Microscopic Colitis ◽  
Everyday Functioning ◽  
Cross Sectional ◽  
Patient Reported

Abstract Background & Aims Patient-reported outcome measures (PROMs) aim to measure patients’ perception of how their disorder influences everyday functioning. The objective of this study was to develop a PROM to assess disease activity in microscopic colitis (MC) fulfilling the requirements of the Food and Drug Administration (FDA). Methods The European Microscopic Colitis Activity Index (E-MCAI) was developed in four steps: 1) A list of symptoms associated with active MC was created by a group of experts in the field. 2) Content validity of the symptoms was performed by experts (n=14) and patients (n=79) using the Content Validity Index. 3) Questions and response alternatives were created for each symptom, and validity of the E-MCAI was evaluated with cognitive interviews with patients (n=7) and by the experts. 4) A pilot postal survey was performed to ensure usability. Results Seven of the symptoms related to active MC fulfilled the criteria for content validity and were included in the E-MCAI: stool consistency, stool frequency, stools at night, feel a need to pass more stools shortly after a bowel movement, urgent need to empty the bowel, leakage of stool, and abdominal pain. The development and validation process resulted in the current version of the E-MCAI consisting of six questions related to MC. Conclusions The E-MCAI was developed using the methods advocated by the FDA. The evaluation indicates good content validity. Further evaluation will be performed to accomplish construct validity, reliability, and responsiveness in future cross-sectional and longitudinal studies.

Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study

Gut ◽  
2016 ◽  
Vol 67 (3) ◽  
pp. 441-446 ◽  
Author(s):  
Thomas G Cotter ◽  
Moritz Binder ◽  
Edward V Loftus ◽  
Rami Abboud ◽  
Meredythe A McNally ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Disease Activity ◽  
Disease Severity ◽  
Clinical Features ◽  
Activity Index ◽  
Disease Activity Index ◽  
Microscopic Colitis ◽  
Physician Global Assessment ◽  
Gi Symptoms

ObjectiveMicroscopic colitis (MC) is a common cause of chronic diarrhoea, often with additional symptoms. No validated instruments exist to assess disease activity in MC, making it difficult to compare efficacy of treatments between clinical trials. We aimed to identify clinical features that independently predicted disease severity and create a Microscopic Colitis Disease Activity Index (MCDAI).DesignPatients with MC were prospectively administered a survey assessing their GI symptoms and the IBD Questionnaire (IBDQ). A single investigator also scored a physician global assessment (PGA) of disease severity on a 10-point scale. Multiple linear regression identified which symptoms best predicted the PGA. These symptoms were then combined in a weighted formula to create the MCDAI. The relationship between MCDAI and the IBDQ was investigated.ResultsOf the 175 patients enrolled, 13 (7.4%) did not complete the survey. The remaining 162 had a median age of 66 years (range, 57–73) and 74% were female. Several clinical features were independently associated with PGA (number of unformed stools daily, presence of nocturnal stools, abdominal pain, weight loss, faecal urgency and faecal incontinence). These parameters were combined to create the MCDAI, which strongly predicted the PGA (R2=0.80). A 1-unit decrease in disease activity (ΔMCDAI) was associated with a 9-unit increase in quality of life (ΔIBDQ).ConclusionsThe MCDAI strongly predicted the PGA and correlated with a validated measure of quality of life. Several symptoms in addition to diarrhoea are associated with disease severity in MC.

Sign in / Sign up

Export Citation Format

Share Document